BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Alpha-1 Antitrypsin Deficiency readouts · AssetMemo
X-WR-CALDESC:Upcoming phase 1/2 and later readouts in Alpha-1 Antitrypsin D
 eficiency\, from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06405633-10846@assetmemo.bio
DTSTAMP:20261121T005651Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:WVE-006: Phase 1/2 readout est. (NCT06405633)
DESCRIPTION:WVE-006\, phase 1/2\, Alpha-1 Antitrypsin Deficiency.\nStudy: A
  Phase 1b/2a\, Open-label Single Ascending Doses and Multiple Ascending Do
 ses Study in Participants With Pi*ZZ AATD\nEstimated primary completion: S
 eptember 2027. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/wve-00
 6#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06
 405633
URL:https://assetmemo.bio/drug/wve-006#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06389877-10771@assetmemo.bio
DTSTAMP:20261121T005651Z
DTSTART;VALUE=DATE:20280531
DTEND;VALUE=DATE:20280601
SUMMARY:BEAM-302: Phase 1/2 readout est. (NCT06389877)
DESCRIPTION:BEAM-302\, phase 1/2\, Alpha-1 Antitrypsin Deficiency.\nStudy: 
 A Study to Evaluate the Safety and Efficacy of BEAM-302 in Adult Patients 
 With Alpha-1 Antitrypsin Deficiency (AATD)\nEstimated primary completion: 
 May 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/beam-302#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT063898
 77
URL:https://assetmemo.bio/drug/beam-302#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06165341-10767@assetmemo.bio
DTSTAMP:20261121T005651Z
DTSTART;VALUE=DATE:20280826
DTEND;VALUE=DATE:20280827
SUMMARY:Fazirsiran: Phase 3 readout est. (NCT06165341)
DESCRIPTION:Fazirsiran\, phase 3\, Alpha-1 Antitrypsin Deficiency.\nStudy: 
 Study to Learn About the Safety of Fazirsiran and if it Can Help People Wi
 th Alpha-1 Antitrypsin Liver Disease With Mild Liver Scarring (Fibrosis)\n
 Estimated primary completion: 26 August 2028. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/fazirsiran#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT06165341
URL:https://assetmemo.bio/drug/fazirsiran#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05677971-10767@assetmemo.bio
DTSTAMP:20261121T005651Z
DTSTART;VALUE=DATE:20290117
DTEND;VALUE=DATE:20290118
SUMMARY:Fazirsiran: Phase 3 readout est. (NCT05677971)
DESCRIPTION:Fazirsiran\, phase 3\, Alpha-1 Antitrypsin Deficiency.\nStudy: 
 Study to Check the Safety of Fazirsiran and Learn if Fazirsiran Can Help P
 eople With Liver Disease and Scarring (Fibrosis) Due to an Abnormal Versio
 n of Alpha-1 Antitrypsin Protein\nEstimated primary completion: 17 January
  2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/fazirsiran#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0567797
 1
URL:https://assetmemo.bio/drug/fazirsiran#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07227207-11307@assetmemo.bio
DTSTAMP:20261121T005651Z
DTSTART;VALUE=DATE:20290331
DTEND;VALUE=DATE:20290401
SUMMARY:TSRA-196: Phase 1/2 readout est. (NCT07227207)
DESCRIPTION:TSRA-196\, phase 1/2\, Alpha-1 Antitrypsin Deficiency.\nStudy: 
 A Study of TSRA-196 in Adults With PiZZ Alpha-1 Antitrypsin Deficiency (AA
 TD)\nEstimated primary completion: March 2029. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/tsra-196#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT07227207
URL:https://assetmemo.bio/drug/tsra-196#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05899673-10767@assetmemo.bio
DTSTAMP:20261121T005651Z
DTSTART;VALUE=DATE:20330502
DTEND;VALUE=DATE:20330503
SUMMARY:Fazirsiran: Phase 3 readout est. (NCT05899673)
DESCRIPTION:Fazirsiran\, phase 3\, Alpha-1 Antitrypsin Deficiency.\nStudy: 
 An Extension Study to Learn About the Long-Term Safety of Fazirsiran and i
 f Fazirsiran Can Help People With Alpha-1 Antitrypsin Liver Disease\nEstim
 ated primary completion: 2 May 2033. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/fazirsiran#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT05899673
URL:https://assetmemo.bio/drug/fazirsiran#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
